FOLH1 and metastatic prostate carcinoma: To determine the expression of PSMA in these clinically relevant subsets, we assessed FOLH1 mRNA levels in 3 cohorts comprising 126 LuCaP prostate cancer patient-derived xenograft (PDX) samples (Figure 1A), 270 Stand Up To Cancer (SU2C) international dream team mCRPC biopsies (Figure 1B), and 172 lethal metastatic prostate cancer samples from the UW rapid autopsy program (UW Tissue Acquisition Necropsy [UW-TAN]) (Figure 1C, Supplemental Figure 1, and Supplemental Tables 1 and 2; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.162907DS1) (24–26).